Temodal (temozolomide) Post Marketing Surveillance Protocol.

Trial Profile

Temodal (temozolomide) Post Marketing Surveillance Protocol.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2013

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme
  • Most Recent Events

    • 08 May 2012 Actual patient number is 682 according to ClinicalTrials.gov.
    • 03 Jan 2012 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
    • 03 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top